
According to Zhitong Finance App, Cinda Biotech (01801) announced that its partner Ollin Biosciences, Inc. (Ollin) has reached an acquisition agreement with Johnson & Johnson (NYSE: JNJ). The Ollin core pipeline OLN324 (Cinda Biotech R&D code: IBI324) was developed by Cinda Biotech and authorized to the outside world.
Ollin was founded in 2023 to discover and accelerate the development of next-generation ophthalmic treatments. Its core pipeline, OLn324, is a bispecific antibody targeting VEGF and Ang2 that is undergoing phase III clinical research worldwide. It has undergone molecular structure optimization and efficacy optimization, and is intended to be used to treat wet age-related macular degeneration (wAMd) and diabetic macular edema (DME). These two types of severe retinal vascular diseases are one of the main causes of blindness in the world, with more than 40 million patients worldwide. Relying on differentiated molecular design and clinical data obtained at this stage, OLN324 is expected to achieve more effective retinal fluid reduction and extend dosage intervals. Recently, OLN324 has initiated the enrollment of patients in global phase III clinical trials with the above two indications.
Over the past few years, the company has worked closely with the Ollin team to jointly advance the clinical development of OLN324/IBI324. Retinal vascular disease affects tens of millions of patients around the world. The common goal of both parties is to make this drug candidate a new, clinically valuable treatment plan. The company is pleased to see its partners reach this important milestone, and the drug candidate is expected to achieve stronger and longer lasting disease control, a potential recognized by leading global pharmaceutical companies. The company will also continue to work with various partners to fully promote project development to benefit retinal vascular disease patients around the world as soon as possible.